Published in Semin Oncol on June 01, 1997
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis (2007) 5.21
Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol (2008) 0.81
Paraneoplastic SIADH and Dermatomyositis in Cervical Cancer: A Case Report and Literature Review. Case Rep Oncol (2009) 0.79
Pityriasis lichenoids chronica as a paraneoplastic dermatosis for primary splenic diffuse large B cell lymphoma. Indian J Hematol Blood Transfus (2014) 0.75
Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer. Dermatol Pract Concept (2015) 0.75
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
Tripe palms and malignancy. J Clin Oncol (1989) 1.27
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Sweet's syndrome and malignancy. Am J Med (1987) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Muir-Torre syndrome. Dermatol Clin (1995) 1.17
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 1.14
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol (1999) 1.09
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med (1993) 1.08
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 1.06
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia (2003) 1.05
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia (1995) 1.05
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest (1994) 1.03
Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res (1986) 1.02
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer (1991) 1.01
Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol (1999) 0.99
Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer (1995) 0.98
Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma (1997) 0.97
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer (1996) 0.97
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol (2012) 0.95
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 0.95
Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med (1995) 0.95
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res (1993) 0.94
Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med (1997) 0.94
Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. Ann Rheum Dis (1993) 0.94
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res (1987) 0.93
Tripe palms and cancer. Clin Dermatol (1993) 0.92
Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol (2001) 0.91
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res (1999) 0.91
Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res (1995) 0.91
The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res (2001) 0.91
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol (2013) 0.91
Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol (1991) 0.90
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol (1997) 0.89
Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol (1986) 0.89
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia (1998) 0.89
Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. Dermatol Clin (1995) 0.89
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Invest New Drugs (2014) 0.89
Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med (1986) 0.89
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia (1997) 0.89
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood (1992) 0.88
High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma (1998) 0.88
Acute febrile neutrophilic dermatosis. Am Fam Physician (1989) 0.87
Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol (2011) 0.87
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol (1996) 0.87
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs (2013) 0.87
Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer (1988) 0.86
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood (1996) 0.85
Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res (1986) 0.85
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res (1995) 0.85
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol (2011) 0.84
Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet (1987) 0.84
Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol (1988) 0.84
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med (1993) 0.84
Extracutaneous manifestations of Sweet's syndrome: steroid-responsive culture-negative pulmonary lesions. Am Rev Respir Dis (1992) 0.84
Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. J Clin Oncol (1986) 0.84
Body composition and survival in the early clinical trials setting. Eur J Cancer (2013) 0.84
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood (2001) 0.83
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol (2012) 0.83
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol (1988) 0.83
Chronic myelogenous leukemia and Sweet syndrome. Am J Hematol (1989) 0.83
A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res (1999) 0.82
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood (1994) 0.82
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res (1992) 0.82
Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (1996) 0.82
Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia (1996) 0.82
Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia (2003) 0.82
Malignancy-associated tripe palms. J Am Acad Dermatol (1992) 0.82
The pathogenesis of Sweet's syndrome. J Am Acad Dermatol (1991) 0.82
Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod (1987) 0.81
CML: mechanisms of disease initiation and progression. Leuk Lymphoma (1993) 0.81
Obstructive lung disease after allogeneic bone marrow transplantation. Transplantation (1984) 0.81
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood (1992) 0.81